New Recruiting Trial: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

WHY IT MATTERS

This trial is recruiting pregnant women with NMOSD who have been exposed to UPLIZNA — currently there is limited safety data on this drug during pregnancy, so this study directly addresses a critical gap for women of childbearing age managing this serious neurological condition.

Researchers are looking for pregnant women with NMOSD (a rare disease that affects the nerves in the eyes and spinal cord) who have taken or are taking a medicine called UPLIZNA to join a safety study. The study will track what happens to these women and their babies to make sure the medicine is safe during pregnancy. This information will help doctors understand whether UPLIZNA can be used safely by pregnant patients with NMOSD.

NCT ID: NCT05909761 Title: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy Status: RECRUITING Sponsor: Amgen Start date: 2026-04-15 URL: https://clinicaltrials.gov/study/NCT05909761 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

If you are a pregnant woman with NMOSD who has taken UPLIZNA or are considering it during pregnancy, contact the study team at the link provided to see if you qualify — enrollment is actively recruiting.